Magnesium orotate in severe congestive heart failure (MACH)

Int J Cardiol. 2009 May 1;134(1):145-7. doi: 10.1016/j.ijcard.2009.01.047.


Background: Aim of this study was to evaluate adjuvant magnesium orotate on mortality and clinical symptoms in patients with severe heart failure under optimal cardiovascular medication.

Methods: In a monocentric, controlled, double-blind study, 79 patients with severe congestive heart failure (NYHA IV) under optimal medical cardiovascular treatment were randomised to receive either magnesium orotate (6000 mg for 1 month, 3000 mg for about 11 months, n = 40) or placebo (n = 39). Both groups were comparable in demographic data, duration of heart failure and pre- and concomitant treatment.

Results: After mean treatment duration of 1 year (magnesium orotate: 364.1 +/- 14.7 days, placebo: 361.2 +/- 12.7 days) the survival rate was 75.7% compared to 51.6% under placebo (p < 0.05). Clinical symptoms improved in 38.5% of patients under magnesium orotate, whereas they deteriorated in 56.3% of patients under placebo (p < 0.001).

Conclusion: Magnesium orotate may be used as adjuvant therapy in patients on optimal treatment for severe congestive heart failure, increasing survival rate and improving clinical symptoms and patient's quality of life.

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Chemotherapy, Adjuvant
  • Female
  • Heart Failure / drug therapy*
  • Heart Failure / mortality
  • Humans
  • Male
  • Middle Aged
  • Orotic Acid / administration & dosage
  • Orotic Acid / adverse effects
  • Orotic Acid / analogs & derivatives*
  • Severity of Illness Index
  • Young Adult


  • Orotic Acid
  • magnesium orotate